| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C14H22N2O |
| Molar mass | 234.343 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Ispronicline (TC-1734,AZD-3480) is an experimental drug which acts as apartial agonist at neuralnicotinic acetylcholine receptors. It progressed to phase II clinical trials for the treatment ofdementia andAlzheimer's disease, but is no longer underdevelopment.[1]
It has also progressed to phase II as a potential treatment for ADHD. With dosages of 50 mg/day showing a significant improvement in ADHD symptoms[2][3]
Ispronicline is subtype-selective, binding primarily to theα4β2subtype. It hasantidepressant,nootropic andneuroprotective effects.[medical citation needed]
Early stage clinical trials showed that ispronicline was well tolerated, with the main side effects beingdizziness andheadache.[4][5][6][7][8] However, mid-stage clinical trials failed to show sufficientefficacy to continue development as a pharmaceutical drug.[1]
Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |